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median follow up of 18 (6-54) months. Eighteen pts have died; 9
from non-relapse causes (8/9 died of infections  GVHD) and 9
from relapse/PD a median of 7 (range 1-38) months post trans-
plant. Day 100 and 1 year NRM was 7% and 35% respectively.
One year overall survival, progression free survival and relapse/PD
incidence were 51%, 18% and 47% respectively. A detailed de-
scription of the MRD and URD pts is shown in Table 1. In
summary, salvage nonmyeloablative conditioning and allogeneic
HCT provides anti-tumor activity in pts with relapsed or refrac-
tory HD who are ineligible for conventional allogeneic transplant.
Future efforts incorporating tumor-speciﬁc antibody therapy after
nonmyeloablative conditioning HCT are being developed in an
effort to improve disease free survival, anti-tumor activity and
overall survival in pts with relapsed or refractory HD.
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To evaluate the impact of timing of dose-reduced allograft in
patients with multiple myeloma, we analyzed 120 patients in a
retrospective study, who were treated with melphalan/ﬂudarabine
as conditioning regimen. The cumulative risk at one year for
treatment-related mortality (TRM) was 18% (95% CI: 12-28%).
In a multivariate analysis, relapse after prior high-dose chemother-
apy was the most signiﬁcant factor for TRM (HR 2.80; 95% CI:
1.16-6.74; p  0.02), relapse (HR 4.14; 95% CI: 2.04-8.38, p 
0.001), event-free (HR 3.11; 95% CI: 1.77-5.46; p  0.001), and
overall survival (HR 2.69; 95% CI: 1.35-5.35; p  0.005). In
addition, relapse was also signiﬁcantly diminished by chronic
GvHD in a time-dependent Cox model (HR 0.37; 95% CI: 0.16-
0.87; p  0.02), while trans-plantation with peripheral blood stem
cells (PBSC) resulted in better overall survival (HR 0.35; 95% CI:
0.14-0.88; p  0.002). In a subgroup of patients with chemosen-
sitivity at time of transplantation and no relapse after a prior
high-dose chemotherapy who were transplanted with PBSC (n 
46), the cumulative risk of TRM at one year was only 8% (95% CI:
1-54%), and the two-year estimated event-free and overall survival
was 60% (95% CI: 42-78%) and 75% (95% CI: 59-91%) for
related (n  34), and 81% (95% CI: 59-100%) and 92% (95% CI:
76-100%) for unrelated donors (n  12). We conclude that dose-
reduced allograft with related and unrelated donors should be
performed at an earlier stage of the disease in patients who are
chemosensitive and without relapse after a prior autograft, result-
ing in a lower TRM and better event-free and overall survival.
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TRANSPLANTATION OF BOYS WITH X-LINKED ADRENOLEUKODYS-
TROPHY WITH UNRELATED-DONOR, PARTIALLY HLA-MISMATCHED
BANKED UMBILICAL CORD BLOOD
Allison, J., Martin, P.L., Szabolcs, P., Driscoll, T., Parikh, S., Wood, S.,
Kurtzberg, J. Duke University Medical Center, Durham, NC
Introduction: X-linked adrenoleukodystrophy causes dysmyeli-
nation and fatal neurodegenerative disease in 30%-50% of affected
patients. Bone marrow transplantation has been shown to prevent
progression of neurologic disease if performed early in the course
of the disease. As some children lack suitably matched bone mar-
row donors, we explored the efﬁcacy of using partially mismatched
unrelated donor umbilical cord blood transplantation to treat this
disease. Methods: Between 11/1996 and 7/03, 10 boys with a
median age of 7 years (range 2-26 years) were prepared for trans-
plantation with busulfan, cyclophosphamide, and ATG and trans-
planted with 4/6 HLA-matched (n  6) or 5/6 (n  4) unrelated
umbilical cord blood. The median cell dose administered by the
graft was 6.84  10e7cells/kg (range 2.83-14.19) and median
CD34 dose was 2.42  10e5/kg (range 0.48-5.46). GvHD prophy-
laxis was given with cyclosporine and steroids. All boys received
stress dose steroids as coverage for adrenal insufﬁciency. Support-
ive care consisted of IVIG, empiric antifungals and antivirals, TPN
without intralipids, and G-CSF. Results: All boys engrafted with
donor neutrophils in a median of 22 days (range 13-48) days.
Platelets reached 50K/uL without transfusion support in a median
of 75 days (range 25-227 days). Two patients (20%) had grade
II-IV acute GvHD (both grade IV) and recovered. All patients are
surviving with durable grafts with median EFS of 330 days (range
94-2523 days). All patients had progressive changes on MRI at the
time of transplant. Those transplanted before the onset of signif-
icant clinical symptoms have all done well (n  6) and have not
experienced progression of neurologic disease. These patients have
also demonstrated normalization of nerve conduction studies post
transplant. Four patient had progressive clinical symptoms in the 2
months before transplant. Three of the four progressed post trans-
plant before stabilizing at a lower level of functioning. One patient,
the oldest at transplant, had progressive visual losses but improve-
ment in neuromotor function and peripheral neuropathy. Conclu-
sions: We conclude that unrelated donor, partially mismatched
cord blood is a viable and readily available alternative donor for
patients with X-linked ALD requiring transplantation therapy.
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DIMINISHED SICKLE CELL ADHESION MOLECULES FOLLOWING BONE
MARROW TRANSPLANTATION (BMT)
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Hospital & RC, Riyadh, Centeral Province, Saudi Arabia; 2. Louisiana
State University, NewOrleans, LA
To determine whether stem cell allograft affects the expression
and interaction of adhesion molecules on both sickle red cell and
endothelial cells, we examined baseline and follow-up of vascular
Table. Results of Nonmyeloablative Conditioning Followed by
Allogeneic HCT for HD Using MRD or URD
MRD
(n  18)
URD
(n  9)
Median follow up of living
patients (range)
36 (12-54)
months
11 (6-24)
months
Disease status at HCT 4 CR, 7 PR,
4 Rel, 3 Ref
1 CR, 4 PR,
4 Ref
Overall response rate 57% (7 CR,
1 PR)
50% (3 CR,
1 PR)
Living patients/status 3 CR, 2 PD 3 CR, 1 Rel
Acute GVHD grade II, III, IV 33%, 11%, 6% 33%, 22%, 0%
1 year chronic extensive
GVHD
50% 60%
Day 100 NRM 11% 0%
One year NRM 39% 26%
One year overall survival 39% 75%
One year progression free
survival
11% 35%
One year Rel/PD incidence 50% 40%
Rel, relapse; Ref, refractory.
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